Interleukin 12 receptor complex (IL-12R) (IL-12R)

The Interleukin 12 (IL-12) receptor complex is a heterodimeric type I cytokine receptor primarily expressed on the surface of T cells and natural killer (NK) cells (UniProt [6, 9]). It consists of two distinct subunits: IL-12 receptor subunit beta-1 (IL-12Rβ1) and IL-12 receptor subunit beta-2 (IL-12Rβ2), which together form a high-affinity binding site for the cytokine IL-12 (PMC [7]). Upon ligand binding, the receptor complex activates the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, specifically recruiting JAK2 and TYK2 to phosphorylate STAT4 (PMC [1], Patsnap [11]). This signaling cascade is a fundamental driver of the immune response, promoting the differentiation of naive CD4+ T cells into Th1 effector cells and stimulating the production of interferon-gamma (IFN-γ) (PMC [7], Frontiers [19]). Dysregulation or overactivation of the IL-12 receptor pathway is a key pathological feature in several chronic inflammatory and autoimmune conditions, such as plaque psoriasis, Crohn's disease, and ulcerative colitis (Wikipedia [5], Practical Gastro [15]). Therapeutic agents like ustekinumab modulate this pathway by binding to the p40 subunit of the IL-12 cytokine, thereby preventing its interaction with the IL-12Rβ1 subunit of the receptor complex (PMC [1, 3]). While these therapies are highly effective in reducing systemic inflammation, they are associated with safety concerns including an increased risk of serious bacterial, fungal, and mycobacterial infections (FDA [4], Wikipedia [5]). Monitoring of biomarkers such as IFN-γ levels and STAT4 phosphorylation can provide insights into the efficacy and biological activity of drugs targeting this complex (PubMed [16, 17]).

Other names

IL-12 receptorIL12RInterleukin-12 receptorCD212

Inhibition of IL-12 signaling by blocking the interaction between the IL-12 cytokine and its receptor complex, typically via monoclonal antibodies binding to the shared p40 subunit of the cytokine or by inhibiting downstream kinases like TYK2.